Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed (Nasdaq: INSM) will release its second-quarter 2026 financial results on Thursday, August 6, 2026. Management will host a conference call for investors at 8:00 a.m. ET that day to discuss the results and provide a business update, with live access by phone and webcast.
Participants can join via U.S. dial-in (888) 210-2654 or international (646) 960-0278 using access code 7862189, or listen through the company website. A telephone replay will be available until August 13, 2026, and the webcast will be archived for 90 days in Insmed’s Investor Relations section.
Insmed (Nasdaq: INSM) reported positive 12-month results from its ongoing open-label extension study of once-daily treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH, WHO Group 1) who completed prior TPIP PAH studies.
Across TPIP Continued (N=60) and Placebo Crossed (N=31) groups, mean six-minute walk distance improved by approximately 56 and 54 meters, respectively, and NT-proBNP levels fell by about 60% (geometric mean ratios 0.40 and 0.41). WHO Functional Class I or II was reached by 78.3% and 80.6% of patients, with more than 25% in Functional Class I. Mean REVEAL Lite 2.0 score improved by 2.0 and 1.4 points, and about 65% of all patients achieved Refined Low Risk status, which is associated with a less than 5% estimated three-year mortality risk.
Once-daily TPIP was generally well tolerated up to 1,280 µg through Month 12. Among 91 patients, treatment-emergent adverse events occurred in 89.0%, serious events in 18.7%, severe events in 16.5%, and 7.7% discontinued due to events. Four deaths were reported, none considered related to TPIP. These findings support continued development, including the recently initiated Phase 3 PALM-PAH trial.
Insmed (Nasdaq: INSM) appointed Samuele Butera as Senior Vice President, General Manager, Global Respiratory, effective June 23, 2026. He will lead the Respiratory Therapeutic Area, report to CEO Will Lewis, and serve on the Executive Committee.
Butera brings more than 20 years of global commercial leadership from Johnson & Johnson, Novartis, Sandoz Biopharmaceuticals, McKinsey, Goldman Sachs, and the United Nations. According to Insmed, his experience supports the launch of BRINSUPRI, potential ARIKAYCE label expansion, and the TPIP development program.
Insmed (Nasdaq: INSM) granted inducement equity awards to 103 new employees under its 2025 Inducement Plan, intended to comply with Nasdaq Listing Rule 5635(c)(4).
On May 29, 2026, employees received 97,091 RSUs and options on 12,850 shares at an exercise price of $106.91, with four-year vesting schedules.
Insmed (Nasdaq: INSM) announced that management will present at the 2026 Goldman Sachs Annual Global Healthcare Conference in Miami on Tuesday, June 9, 2026, at 10:00 a.m. ET. A live webcast and 30-day replay will be available on Insmed's investor relations website.
Insmed (Nasdaq: INSM) reported total Q1 2026 revenues of $306.0M, led by BRINSUPRI $207.9M (44% growth vs Q4 2025) and ARIKAYCE $98.1M (6% growth vs Q1 2025). Net loss was $163.6M ($0.76/share). Cash, equivalents and marketable securities totaled ~$1.2B.
Key operational updates: UK approval for BRINSUPRI, ENCORE Phase 3b met primary and multiplicity-controlled secondary endpoints for ARIKAYCE in MAC lung disease, PALM-PAH initiated, and the company reiterated 2026 guidance: BRINSUPRI ≥ $1B and ARIKAYCE $450–$470M.
Insmed (Nasdaq: INSM) launched Suspect Bronchiectasis (Suspect BE), an educational initiative with Ty Pennington to raise awareness and improve diagnosis of bronchiectasis. The campaign encourages people with unresolved respiratory symptoms to consult a pulmonologist and consider additional testing such as a CT scan.
The program highlights symptom overlap with COPD and asthma and directs people to SuspectBE.com and social channels for resources and Ty Pennington's caregiver story.
Insmed (Nasdaq: INSM) will present six abstracts at ATS 2026 (May 17–20), including a late-breaking Phase 3b ENCORE presentation of ARIKAYCE for newly diagnosed Mycobacterium avium complex lung disease. Additional data include a post-hoc BRINSUPRI analysis, TPIP pharmacokinetics, real-world bronchiectasis burden, and PH-ILD outcomes.
Insmed also provided an independent research grant to the American Thoracic Society for a nationwide bronchiectasis diagnosis quality initiative.
Insmed (NASDAQ: INSM) announced management presentations at two investor conferences in May 2026: BofA Securities 2026 Healthcare Conference in Las Vegas on May 12, 2026 at 1:40 p.m. PT, and the 2026 RBC Capital Markets Global Healthcare Conference in New York City on May 20, 2026 at 10:30 a.m. ET. Webcasts will be available via the company's investor relations website and archived for 30 days.
Insmed (Nasdaq: INSM) will release first-quarter 2026 financial results on Thursday, May 7, 2026 and host a conference call at 8:00 a.m. ET that day. Management will discuss financial results and provide a business update.
The live call will be webcast at www.insmed.com; a replay will be available by phone through May 14, 2026 and archived on the investor site for 90 days.